Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for stage I-III HER2-positive breast cancer: Results of a single-arm pilot clinical trial

被引：0
|
作者：
Jiang, Jun [1 ]
机构：
[1] Army Med Univ, Chongqing, Peoples R China
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS11-24
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A multicenter single-arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer
    Shi, Qiyun
    Qi, Xiaowei
    Tang, Peng
    Fan, Linjun
    Chen, Li
    Wang, Shushu
    Liang, Yan
    Hu, Ying
    Wang, Minghao
    Ren, Lin
    Zhang, Guozhi
    Tan, Xuanni
    Yuan, Long
    Du, Junze
    Wu, Xiujuan
    Wang, Mengyuan
    Che, Hongying
    Lv, Pengwei
    Chen, Dejie
    Hu, Jinhui
    Li, Qiuyun
    Zhang, Yanwu
    Yang, Kunxian
    Zhong, Yuan
    Chen, Chuang
    Zhou, Zemin
    Qian, Liyuan
    Zhang, Jingwei
    Ma, Mingde
    Sun, Yi
    Zhang, Yi
    Jiang, Jun
    MEDCOMM, 2023, 4 (06):
  • [2] Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-PositiveBreast Cancer: A PhaseIIClinical Trial
    Xuhong, Juncheng
    Qi, Xiaowei
    Tang, Peng
    Fan, Linjun
    Chen, Li
    Zhang, Fan
    Tan, Xuanni
    Yan, Wenting
    Zhong, Ling
    He, Cheng
    Liang, Yan
    Ren, Lin
    Wang, Minghao
    Zhang, Yi
    Jiang, Jun
    ONCOLOGIST, 2020, 25 (12): : E1909 - E1920
  • [3] Epirubicin, cyclophosphamide and pyrotinib followed by docetaxel, trastuzumab and pyrotinib as neoadjuvant therapy for stage II-III HER2-positive breast cancer: a single-arm, multicenter phase 2 trial
    Shi, Qiyun
    Qi, Xiaowei
    Tang, Peng
    Fan, Linjun
    Chen, Li
    Wang, Shushu
    Zhang, Guozhi
    Wang, Mengyuan
    Che, Hongying
    Lv, Pengwei
    Chen, Dejie
    Hu, Jinhui
    Li, Qiuyun
    Zhang, Yanwu
    Yu, Qiao
    Yang, Kunxian
    Zhong, Yuan
    Chen, Chuang
    Zhou, Zemin
    Qian, Liyuan
    Zhang, Jingwei
    Ma, Mingde
    Sun, Yi
    Liu, Jiangbo
    Zhang, Yi
    Jiang, Jun
    CANCER RESEARCH, 2023, 83 (05)
  • [4] Clinical observation of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER2-positive breast cancer: a cohort study
    Li, Qi
    Wang, Yanyan
    Zhu, Mingzhi
    Gu, Yuanting
    Tang, Yajing
    GLAND SURGERY, 2021, 10 (12) : 3389 - 3402
  • [5] Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
    Liu, Lu
    Zhu, Mingzhi
    Wang, Yanyan
    Li, Muhan
    Gu, Yuanting
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [6] Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
    Lu Liu
    Mingzhi Zhu
    Yanyan Wang
    Muhan Li
    Yuanting Gu
    World Journal of Surgical Oncology, 21
  • [7] Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial
    Cao, Jun
    Teng, Yuee
    Li, Huiping
    Zhang, Lili
    Ouyang, Quchang
    Xie, Weimin
    Pan, Yueyin
    Song, Zhenchuan
    Ling, Xiaoling
    Wu, Xiaohong
    Xu, Jingwei
    Li, Li
    Ren, Liping
    Wang, Hong
    Zhou, Dongxian
    Luo, Jing
    Hu, Xichun
    BMC MEDICINE, 2023, 21 (01)
  • [8] Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial
    Jun Cao
    Yuee Teng
    Huiping Li
    Lili Zhang
    Quchang Ouyang
    Weimin Xie
    Yueyin Pan
    Zhenchuan Song
    Xiaoling Ling
    Xiaohong Wu
    Jingwei Xu
    Li Li
    Liping Ren
    Hong Wang
    Dongxian Zhou
    Jing Luo
    Xichun Hu
    BMC Medicine, 21
  • [9] Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial
    Yan, Min
    Niu, Limin
    Lv, Huimin
    Zhang, Mengwei
    Wang, Jing
    Liu, Zhenzhen
    Chen, Xiuchun
    Lu, Zhenduo
    Zhang, Chongjian
    Zeng, Huiai
    Zhao, Shengnan
    Feng, Yajing
    Sun, Huihui
    Li, Huajun
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [10] Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial
    Min Yan
    Limin Niu
    Huimin Lv
    Mengwei Zhang
    Jing Wang
    Zhenzhen Liu
    Xiuchun Chen
    Zhenduo Lu
    Chongjian Zhang
    Huiai Zeng
    Shengnan Zhao
    Yajing Feng
    Huihui Sun
    Huajun Li
    Nature Communications, 14
12345